IRB #

STUDY00020930

Title

[NCI CIRB] A051701 - Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Principal Investigator

Craig Okada

Study Purpose

Participation in this study is to compare adding either venetoclax plus usual chemotherapy compared to the usual chemotherapy in patients with double-hit lymphoma.

Medical Condition(s)

Diffuse Large B-Cell Lymphoma
Double-Expressor Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
High Grade B-Cell Lymphoma, Not Otherwise Specified
Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present

Eligibility Criteria

Pathologic diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL) or High grade B-Cell Lymphoma (HGBCL)

No prior treatment for DLBCL/HGBCL is allowed with the exception of corticosteroids administered for palliation, or a single cycle of either R-CHOP or DA-EPOCH-R administered prior to enrollment.

Greater than 18 years of age

Performance status of 0 to 2

Lab values within parameters

Not pregnant or nursing

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

10 years post registration

Minors Included

No

Contact

Knight Information Line - trials@ohsu.edu or 503-494-1080

Sponsor

Alliance

Recruitment End

01/31/2022

Compensation Provided

No


Go Back